The effects of ionizing radiation (IR) on tumor neovascularization are still unclear. We previously reported that vascular endothelial cells (ECs) expressing the IR-induced senescence-like (IRSL) phenotype exhibit a significant decrease in angiogenic activity in vitro. In this study, we examined the effects of the IRSL phenotype on adhesion to early endothelial progenitor cells (early EPCs). Adhesion of human peripheral blood-derived early EPCs to human umbilical vein endothelial cells (HUVECs) expressing the IRSL phenotype was evaluated by an adhesion assay under static conditions. It was revealed that the IRSL HUVECs supported significantly more adhesion of early EPCs than normal HUVECs. Expressions of ICAM-1, VCAM-1 and E-selectin were up-regulated in IRSL HUVECs. Pre-treatment of IRSL HUVECs with adhesion-blocking monoclonal antibodies against E-selectin and VCAM-1 significantly reduced early EPC adhesion to IRSL HUVECs, suggesting a potential role for the E-selectin and VCAM-1 in the adhesion between IRSL ECs and early EPCs. Therefore, the IRSL phenotype expressed in ECs may enhance neovascularization via increased homing of early EPCs. Our findings are first to implicate the complex effects of this phenotype on tumor neovascularization following irradiation.
INTRODUCTION
Although radiotherapy is one of the major cancer treatment modalities, the effects of ionizing radiation (IR) on tumor neovascularization remain largely unknown. [1] [2] [3] [4] It is quite important to resolve the question because the neovascularization strongly affects the radioresponse of tumors. [5] [6] [7] We previously reported that after irradiation, the exponentially growing ECs exhibited the typical IRSL phenotype efficiently rather than apoptosis; flattened and enlarged cell morphology, permanent withdrawal from cell cycle, and increased activity of β-galactosidase (β-Gal) activity. Interestingly, IRSL ECs showed a significantly reduced angiogenic activity in vitro. 8) We thus proposed a hypothesis that the IR-induced senescence-like (IRSL) phenotype of ECs could contribute to inhibition of tumor neovascularization. 8) Tumor neovascularization is also supported by the function of endothelial progenitor cells (EPCs) derived from the bone marrow. [9] [10] [11] EPCs were first reported by Asahara et al. 12) who described the differentiation of cells bearing ECmarkers from peripheral blood mononuclear cells that were enriched for glycoprotein CD34 or VEGF receptor 2 expression. 12) These EPCs are thought to contribute to revascularization and the salvage of ischemic hind limbs and to be involved in vascular homeostasis and repair, neovascularization, and various cardiovascular diseases. [12] [13] [14] [15] [16] [17] [18] EPCs consist of two different subpopulations, termed early EPCs, also known as early outgrowth EPCs, and late EPCs, also known as late outgrowth EPCs. [19] [20] [21] [22] [23] Both early and late EPCs act synergistically to enhance in vivo neovascularization in several disease models. [24] [25] [26] It was recently reported that early EPCs are thought to play an initial role in tumor neovascularizaion. 20, 27) In this study, we characterized the interactions of early EPCs with IRSL ECs and discussed the possible role of the IRSL phenotype of ECs in neovascularization.
MATERIALS AND METHODS

Cell lines and culture conditions
Human umbilical vein endothelial cells (HUVECs) purchased from Cambrex (Walkerville, MD) were maintained according to the manufacturer's instructions. Exponentially growing HUVECs (1 × 10 4 ) were grown on collagen I coated 96 well plates, beginning at passage number 2-3 and incubated for 24 h. To generate ECs expressing the IRSL phenotype, exponentially growing cells were incubated for 5 days after being exposed to 8 Gy of γ-rays irradiation at a dose rate of 0.72 Gy/min using a 60 Co γ-ray therapeutic machine (Toshiba, Tokyo, Japan). To confirm the IRSL phenotype of cells, the senescence-associated β-galactosidase (β-gal) assay was performed using a β-gal staining kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, except that staining was performed at pH 6.0, as previously described. 8, 28) At the indicated times after irradiation, cells were fixed in 1 × Fixative Solution (Invitrogen) for 10 mins and washed in phosphate buffered saline (PBS) twice. Cells were then stained in Staining Solution (Invitrogen) at pH 6.0 for 10 hours and the reaction was stopped with 70% glycerol. 8) HL-60, a leukocytic cell line, were obtained from American Type Culture Collection and grown in RPMI1640 medium containing 10% FBS, 100 U/mL of penicillin, 100 μg/mL of streptomycin and 2 mM Lglutamine. 29) Early EPCs were prepared by plating peripheral blood mononuclear cells from human volunteers on human fibronectin coated (Sigma-Aldrich, St. Louis, MO) culture dishes and maintained in endothelial cell basal medium-2 (Cambrex, Walkersville, MD) supplemented with 5% FBS, human vascular endothelial growth factor-A, human fibroblast growth factor-2, human epidermal growth factor, insulin-like growth factor-1, and ascorbic acid. After 4 days of culture, nonadherent cells were removed by washing with PBS, and then cultured 3 more days before use in the adhesion assay, as previously described. 19) Early EPCs as obtained after 7 days of culture were confirmed by the surface expression of markers for endothelial cells (CD34 + , CD31 + , and vascular endothelial growth factor receptor 2 + ) and uptake of DiI acetylated LDL. 19, 30) The experimental protocol was approved by the Experimental Research Review Committee (no. 0090014).
Quantitative static adhesion assay
To characterize EC-early EPC adhesion, EPCs (10 6 cells/ mL) were labelled with the fluorescent probe, 3'-O-Acetyl-2',7'-bis(carboxyethyl)-4 or 5-carboxyfluorescein diacetoxymethyl ester (BCECF) (Dojindo Laboratories, Kumamoto, Japan) 2 μL per mL of EPCs. Early EPCs labelled with BCECF were added to HUVEC monolayers (100 μL /well). After incubated for 10 minutes at 37°C under static condition, the unbound early EPCs were separated by plate inversion and centrifugation for 5 minutes in Dynatech plate carriers. After solubilization of well contents with 0.1% sodium dodecyl sulphate (SDS) in 50 mM Tris-HCl (pH 8.5), fluorescence intensity was measured in a microtiter plate fluorimeter (Pandex, FCA, USA) set at 485 nm (excitation)/530 nm (emission), as previously described. 31, 32) To prepare inflammatory activated HUVECs, HUVEC monolayers were pre-incubated with IL-1β 10 U/mL for 4 hours then washed three times with RPMI/1% FBS before using in the adhesion assay. 15) For characterization of HUVECs -HL60 adhesion, HL60 (10 6 cells/mL) were used instead of early EPCs in static adhesion assay, as described above. To determine the adhesion molecules responsible for the early EPC -EC adhesion, HUVEC monolayers were pre-incubated with functional blocking antibodies against mouse anti-E-selectin (7A9), mouse anti-intercellular adhesion molecule-1 (ICAM-1) (Hu5/3), human anti-vascular cell adhesion molecule (VCAM-1) (R & D Systems, Minneapolis, MN) and the control (W6/32, HLA-A,B,C) at 10 μg/mL for 20 minutes before performing quantitative static adhesion assay. The results were compared with those without functional blocking mAb. The results which significantly blocked the EPC adhesion suggested a potential role of the adhesion molecule in the adhesion between ECs and EPCs. 15) Surface Immunofluorescence Assay HUVEC monolayers in 96-well plates were incubated on ice with the indicated primary mAb including mouse anti-Eselectin (7A9), mouse anti-ICAM-1(Hu5/3), human anti-VCAM-1 (R & D Systems, Minneapolis, MN) and control mAb(W6/32) in RPMI/1% FBS at 10 μg/mL for 45 minutes. Wells were washed three times with RPMI/1% FBS and then incubated with the fluorescent probe, FITC-conjugated goat anti-mouse polyclonal F(ab')2 antibody (Invitrogen, Carlsbad, CA), dilute 1: 250 in Dulbecco's PBS on ice. After 45 minutes, wells were washed twice with Dulbecco's PBS/ 10% FBS and twice with Dulbecco's PBS alone. Cells were lysed with 0.01% NaOH in 0.1% SDS (pH 8.6), and fluorescence was quantified using a microtiter plate fluorimeter (Pandex, FCA, USA) set at 485 nm (excitation)/530 nm (emission), as previously described. 33) To identify the surface adhesion molecules expression in the inflammatory activated HUVECs, HUVEC monolayers were stimulated with IL-1β 10 U/mL for 4 hours then were washed three times with RPMI/1% FBS before using in the surface immunofluorescence assay.
Statistical Analysis
All results were expressed as means ± SEM. Statistical significance was evaluated using either a Student's t-test or one-way ANOVA with Tukey post hoc test. A value of P less than 0.05 was considered to denote statistical significance.
RESULTS
Characterization of IRSL phenotype of HUVECs
We first examined the IRSL phenotype of the irradiated HUVECs by senescence-associated β-Gal assay together with microscopic inspection of cell morphology. We found that most of HUVECs (over 80 percent) exhibited an enlarged and flattened cell shape with increased β-Gal activity at the fifth day after being subjected to 8 Gy of irradiation (Fig. 1A, B) , which confirmed our previous results.
Increased adhesion of early EPCs to HUVECs expressing the IRSL phenotype under the static condition
To evaluate the adhesive interaction between ECs and EPCs, we utilized the quantitative leukocyte-endothelial monolayer adhesion assay (static condition), which was initially designed to investigate adhesion-stimulatory or -inhibitory substances that might act on either leukocytes or endothelial cells and to characterize the ligand-receptor pairs involved in this process.
31) The EPCs used in this study were confirmed to be early EPCs based on the expression of CD34, CD31, VEGFR2 and uptake of DiI acetylated LDL. To demonstrate adhesion between IRSL ECs and early EPCs, we performed the adhesion assay using IRSL HUVECs and early EPCs, as described in the Materials and Methods. We found that IRSL HUVECs supported significantly greater levels of early EPCs adhesion as compared to normal HUVECs. In addition, when normal HUVEC monolayers were activated with IL-1β, a cytokine that is strongly upregulated during inflammation, early EPCs showed significantly more adhesion than unstimulated HUVECs. Interestingly, IRSL HUVECs supported significantly greater levels of early EPC adhesion as compared to IL-1β-stimulated HUVECs ( Fig. 2A) .
We then compared the adhesive interactions between early EPCs and the leukocytic cell line, HL60. HL60 cells significantly adhered to IRSL HUVECs and IL-1β-stimulated HUVECs as compared to normal HUVECs. In addition, IL-1β-stimulated HUVECs supported significantly greater levels of HL60 adhesion as compared with IRSL HUVECs (Fig. 2B) .
Expressions of ICAM-1, VCAM-1 and E-selectin are upregulated in IRSL HUVECs
Next, we investigated adhesion molecule expression in IRSL HUVECs using surface immunofluorescence assay. We found that IRSL HUVECs significantly exhibited greater levels of ICAM-1, VCAM-1 and E-selectin as compared to normal HUVECs. Expressions of ICAM-1, VCAM-1 and Eselectin were also upregulated in IL-1β-stimulated HUVECs. While expression of ICAM-1 was significantly greater in IL-1β-stimulated HUVECs, that of VCAM-1 and E-selectin was significantly higher in IRSL HUVECs (Fig.  3A 3B, 3C ).
E-selectin and VCAM-1 play a potential role in adhesion of early EPCs and IRSL HUVECs
To determine the adhesion molecules responsible for early EPC adhesion, IRSL HUVECs were pre-incubated with functional blocking antibodies against ICAM-1, VCAM-1 and E-selectin and control mAb (W6/32, HLA-A,B,C), and the results were compared to those without functional blocking antibodies. As shown in Fig. 4 , pretreatment with E-selectin and VCAM-1mAb, but not ICAM-1 mAb, significantly blocked the adhesion of early EPCs to IRSL HUVECs, suggesting a potential role of E-selectin and VCAM-1 in IRSL HUVEC-early EPC adhesion.
DISCUSSION
Recently, EPCs were reported to play an important role in tumor neovascularization. 20, 27) Two types of EPCs can be discriminated based on their surface antigen expression, proliferation potential, and time of emergence in cell culture. 22) Early EPCs, also known as early outgrowth EPCs, originate after ~7 days of culture. 22) Early EPCs possess transient proliferative potential in vitro and cannot be passaged for a long period. 20) The other type of EPCs is late EPCs, also known as late outgrowth EPCs. 21, 23, 34) Late EPCs emerge after 14 -28 days in culture as colonies with a cobblestone-appearance and display an almost indefinite proliferation potential. 21, 23, 34) Through a paracrine mechanism, including the secretion of high levels of IL-8 and VEGF, early EPCs augment the proliferation, migration, and the capillary tube forming capabil- ities of late EPCs. 24) Recruited early EPCs first adhere to the endothelium 20, 35) and create a temporary capillary-like scaffold for the neovasculature. 20, 36, 37) In a later phase, these early EPCs are replaced by either late EPCs or mature ECs. Pro-angiogenic stimuli secreted by either early or late EPCs 18, 29) result in the production of an angiogenic microenvironment that stimulates the nearby endothelium to proliferate and cover the capillary-like tunnel walls. These findings indicate that early EPCs play a pivotal role in the initial step of tumor neovascularization. 20, 27) We previously reported that IR could induce significant levels of the senescence-like phenotype in exponentially growing ECs rather than apoptosis in vitro, the phenotype of which is associated with the DNA double strand break repair activity of ECs.
38) The phenotype was accompanied by a significant reduction in angiogenesis in vitro. 8) Thus, these findings strongly suggest that the IRSL phenotype expressed in ECs following IR may contribute to the inhibition of angiogenic activity within tumors in vivo. However, tumor neovascularization is also supported by the function of bone marrow-derived EPCs as described above. [9] [10] [11] We thus attempted to explore the effect of the IRSL phenotype on tumor neovascularization assuming the interactions with early EPCs from outside of the irradiation fields. Considering that tumor tissue-derived endothelial cells exhibit different phenotypes from normal endothelial cells, [39] [40] [41] those cells should be an appropriate in vitro experimental model to study the tumor neovascularization process. This type of model, however, is not readily available, and we reasoned that using HUVECs is still useful to speculate such a process in vivo. Indeed, many investigators still use HUVECs as an in vitro model of tumor angiogenesis. [42] [43] [44] [45] Although it has been reported that inflammation-activated ECs support significantly more adhesion of early EPCs compared to inactivated ECs, 15, 20, 46) the properties of early EPC adhesion in IRSL ECs have not been carefully studied. We have demonstrated that IRSL ECs support greater levels of early EPC adhesion than normal ECs. The interaction of leukocytes with activated endothelial cells begins when the leukocytes roll on the endothelial monolayer, an interaction that is primarily supported by the selectin family of adhesion molecules, after which they stably adhere via integrin and ICAM-1/VCAM-mediated interactions. Early EPCs also follow the same adhesive interaction cascade that occurs in the inflamed ECs. 15) In this study, we found that E-selectin and VCAM-1 overexpressed in IRSL ECs play a role in adhesion to EPCs. This is in agreement with previous reports showing a potential role of E-selectin and VCAM-1 in EPC-EC interactions during inflammation. Because E-selectin and VCAM-1 appear to play only a modest functional role, it is possible that some other molecules including integrins may play more important roles in enhanced adhesion of early EPCs to HUVECs. Alternatively, many adhesion molecules are involved in this process and, therefore, specific inhibition of one molecule may be ineffective. Further clarification of these processes will require additional research.
Taken together with our previous report, we could propose the following model regarding the endothelial radioresponse. After irradiation, proliferating, actively angiogenic ECs at the angiogenic site in tumor vessels exhibit the IRSL phenotype and decrease their angiogenic activity. On the other hand, such ECs recruit more early EPCs via overexpression of adhesion molecules including VCAM-1 and Eselectin, and rather might enhance neovascularization. Therefore, the role of the IRSL phenotype in ECs is thus complex and the total activity of tumor neovascularization may be regulated by the balance between these two processes. Although this model is based on several speculations and requires further investigation, our results are first to implicate a complex role for the IRSL phenotype of ECs in tumor neovascularization following irradiation.
